Brief: Aim Vaccine Says Freeze-Dried Human Rabies Vaccine Candidate Obtained Clinical Trial Approval
24/10/2022 02:10
Oct 24 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* FREEZE-DRIED HUMAN RABIES VACCINE CANDIDATE OBTAINED
CLINICAL
TRIAL APPROVAL ISSUED BY NATIONAL MEDICAL PRODUCTS
ADMINISTRATION
Source text for Eikon: ID:
Further company coverage: 6660.HK
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine